Shire has previously inked a deal with Glaxosmithkline (GSK) to co-promote Vyvanse, Shire’s new drug for the treatment of attention deficit and hyperactivity disorder. The agreement is expected to add 600 US sales representatives from GSK to Shire’s 600 employees working on the promotion of Vyvanse, reported the news source.
Shire believes that the combined sales force will help complement the promotion efforts of both the companies since GSK’s sale force is focusing primarily on adult specialists in the primary care sector while its sale force is targeting specialists in the pediatric area.